A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers

Launched by ALNYLAM PHARMACEUTICALS · Nov 4, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called ALN-AGT01 RVR to see how safe it is and how the body processes it when given to healthy adults. The study is currently recruiting volunteers between the ages of 18 and 65 who have a healthy weight. To be eligible, participants must not have any serious liver or kidney issues, and they should not have certain infections like HIV or hepatitis.

If you decide to participate, you'll receive a single dose of the study drug, and the researchers will monitor you closely to check for any side effects and how the drug behaves in your body. This trial is an important step in understanding this new treatment, and your involvement could help advance medical knowledge. Remember, it's crucial to discuss any questions or concerns with your healthcare provider before joining a study like this.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Is an adult healthy volunteer
• • Has a body mass index ≥18 kg/m\^2 and ≤28 kg/m\^2
• • Exclusion Criteria
• • Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> upper limit of normal (ULN)
• • Has known human immunodeficiency virus infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
• • Has an estimated glomerular filtration rate (eGFR) of \<90 mL/min/1.73m\^2 at screening
• • Note: other protocol defined inclusion / exclusion criteria apply